# Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

> **NCT05510427** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Cholangiocarcinoma
- Liver Cancer

## Interventions

- **DRUG:** Infigratinib
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05510427
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-08-07
- **Primary completion:** 2023-08-07
- **Final completion:** 2023-08-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Per PI's request
- **Last updated:** 2023-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05510427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05510427, "Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05510427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*